KN-62

KN62 is a P2X7R antagonist (hP2X7 IC50 = 51 nM) and Ca2+/calmodulin-dependent protein kinase II inhibitor. KN62 inhibits the invasiveness of cancer cells in vitro and in vivo KN62 causes retrograde amnesia in the rat. KN62 attenuates glutamate release by inhibiting voltage-dependent Ca(2+)-channels. The effect of KN62 on Ca(2+)-influx appears to be specific to slowly-or non-inactivating conductances, and therefore presents KN62 as a potentially useful tool.

Product information

CAS Number: 127191-97-3

Molecular Weight: 721.84

Formula: C38H35N5O6S2

Synonym:

KN 62

KN62

KN-62

Chemical Name:  (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate

Smiles: CN([C@@H](CC1C=CC(=CC=1)OS(=O)(=O)C1=CC=CC2=CN=CC=C12)C(=O)N1CCN(CC1)C1C=CC=CC=1)S(=O)(=O)C1=CC=CC2=CN=CC=C12

InChiKey: RJVLFQBBRSMWHX-DHUJRADRSA-N

InChi: InChI=1S/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9-3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3/t35-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

KN-62 is a selective antagonist of Ca2+/calmodulin-dependent protein kinase II (CaMKII). KN-62 potently antagonizes ATP-stimulated Ba2+ influx into fura-2 loaded human lymphocytes with an IC50 of 12.7±1.5 nM (n=3) and complete inhibition of the flux at a concentration of 500 nM. Similarly, KN-62 inhibits ATP-stimulated ethidium+ uptake, measured by time resolved flow cytometry, with an IC50 of 13.1±2.6 nM (n=4) and complete inhibition of the flux at 500 nM. KN-62 is found to be a potent antagonist in a functional assay, inhibition of ATP-induced K+efflux in HEK293 cells expressing recombinant human P2X7 receptors. In human leukemic B lymphocytes, KN-62 reduces the rate of permeability increase to larger permeant cations, like ethidium, induced by Bz-ATP with an IC50 of 13.1 nM. KN-62 at a concentration of 3 µM has no effect on ATP-induced ethidium influx through the rat P2X7 receptor, while the IC50 at the human P2X7 receptor is 0.1 µM. KN-62 has considerable selectivity for P2X7 receptors within the P2 family.

In Vivo:

The antidepressant-like behavior of ZnCl2 (10 mg/kg, p.o.) (p<0.01) is prevented by CAMKII inhibitor KN-62 (1 μg/site, i.c.v.). The two-way ANOVA reveals a significantly main effect of KN-62 treatment [F(1, 28)=27.47, p<0.01], no main effect of ZnCl2 treatment [F(1, 28)=0.84, p>0.05] and a significant effect of KN-62×ZnCl2 treatment interaction [F(1, 28)=22.57, p<0.01] to immobility time. As revealed by the post-hoc analysis, the anti-immobility effect of ZnCl2 is completely prevented by treatment of animals with KN-62. No effect in locomotor activity in the open-field test is observed: (KN-62 treatment [F(1, 24)=1.97, p>0.05], ZnCl2 treatment [F(1, 24)=3.99, p>0.05] and KN-62×ZnCl2 treatment interaction [F(1, 24)=0.61, p>0.05]).

References:

1. Park JH, Lee GE, Lee SD, Hien TT, Kim S, Yang JW, Cho JH, Ko H, Lim SC, Kim YG, Kang KW, Kim YC. Discovery of novel 2,5-dioxoimidazolidine-based P2X(7) receptor antagonists as constrained analogues of KN62. J Med Chem. 2015 Mar 12;58(5):2114-34. doi: 10.1021/jm500324g. Epub 2015 Feb 23. PubMed PMID: 25597334.
2. Baraldi PG, Romagnoli R, Tabrizi MA, Falzoni S, di Virgilio F. Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor. Bioorg Med Chem Lett. 2000 Apr 3;10(7):681-4. PubMed PMID: 10762053.
3. Enns L, Murray D, Mirzayans R. Effects of the protein kinase inhibitors wortmannin and KN62 on cellular radiosensitivity and radiation-activated S phase and G1/S checkpoints in normal human fibroblasts. Br J Cancer. 1999 Nov;81(6):959-65. PubMed PMID: 10576651; PubMed Central PMCID: PMC2362948.

Products are for research use only. Not for human use.